Revolution Medicines (RVMD) Net Income towards Common Stockholders (2019 - 2026)

Revolution Medicines' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$453.8 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 112.64% year-over-year to -$453.8 million; the TTM figure through Mar 2026 stood at -$1.4 billion (down 96.66% YoY), while the FY2025 annual figure was -$1.1 billion, down 88.52% from the prior year.
• Net Income towards Common Stockholders was -$453.8 million for Q1 2026 at Revolution Medicines, down from -$364.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$56.5 million in Q4 2022 to a low of -$453.8 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$168.8 million across 5 years, with a median of -$133.2 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Net Income towards Common Stockholders retreated 7.31% in 2022, then sank 185.77% in 2023.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$56.5 million in 2022, then tumbled by 185.77% to -$161.5 million in 2023, then slipped by 20.45% to -$194.6 million in 2024, then sank by 87.54% to -$364.9 million in 2025, then decreased by 24.37% to -$453.8 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$453.8 million (Q1 2026), -$364.9 million (Q4 2025), and -$305.2 million (Q3 2025), per Business Quant data.